If you've spent any time investing on the ASX, you've likely heard of a "10-bagger": the kind of stock that grows tenfold from its starting point.
Finding a true 10-bagger is no easy feat.
It's not just about spotting a quality business early — one that can innovate, scale, and execute — but also having the patience to hold it long enough for compounding to do its work. Overnight successes are rare; most long-term winners take years of persistence to reveal their potential.
4DMedical Ltd (ASX: 4DX) could be one such company.
This ASX tech stock has already delivered impressive gains. At the time of writing, the share price has surged 281% in the past year, recently trading near $1.98 after touching a 52-week high of $2.55. From its lows of just 23 cents, that's already more than a 10-fold move from trough to top for perfect timers.
But could there be another act to come?
Image source: Getty Images
A new frontier in medical imaging
4DMedical is a medical technology company commercialising its patented "four-dimensional" imaging platform known as XV Technology. It allows doctors to view and measure how air moves through the lungs — non-invasively, in real time, and at a fraction of the radiation dose of traditional scans.
Its core products include the XV LVAS and CT LVAS software systems, which analyse lung function using X-ray or CT hardware, and the company's prototype XV Scanner, designed for hospitals requiring faster throughput and lower exposure levels.
These aren't science projects. These are commercially launched products with growing adoption across radiology networks such as I-MED and US hospitals, including the University of Miami.
Perhaps most compelling is 4DMedical's focus on the US Veterans Affairs (VA) and Department of Defense (DoD) markets. Millions of veterans have been exposed to toxins from burn pits, and the US PACT Act has allocated US$280 billion over the next decade for affected healthcare programs.
If 4DMedical's technology becomes part of standard screening, even a fraction of that market could represent hundreds of millions in annual revenue.
The anatomy of a 10-bagger
Investors often assume a "10-bagger" requires lightning-fast growth. However, the maths tells a different story.
At a 10% compound annual growth rate (CAGR), it takes roughly 25 years for an investment to grow tenfold.
At 15% CAGR, it takes 17 years.
And at 20% CAGR, it takes 12 years.
The takeaway? Sustained compounding — not overnight hype — turns small innovators into enduring winners. Companies like Pro Medicus (ASX: PME), whose founder Dr Sam Hupert now advises 4DMedical, are living proof that medical software can scale globally when the economics line up.
If 4DMedical can deliver on its US expansion roadmap, the compounding story could just be beginning. The near-term priorities are clear — expand US contracts, deepen adoption within Veterans Affairs and Defence, and secure a Category I CPT insurance code to unlock national reimbursement.
With strong margins and a potential $250 million-a-year revenue stream from VA scans alone, even partial success on these fronts could justify a much higher valuation in the future.
High stakes, higher potential
Of course, this is still an early-stage med-tech business. The company is burning around $8 million per quarter and must prove its technology can achieve large-scale commercial use.
Delays in regulatory approvals, slower adoption by the VA, or the loss of key personnel could all hinder progress. The shares are also priced for success after a huge run, which means volatility is to be expected.
Still, with visionary leadership, world-first technology, and a global market measured in billions, 4DMedical is one ASX tech stock that may just have what it takes to breathe new life into the 10-bagger dream.
